California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Novo Nordisk and Eli Lilly are reducing prices for their widely used obesity medications, Wegovy and Mounjaro, in China, a move that could significantly expand patient access in one of the world’s largest pharmaceutical markets. The price adjustment comes as China faces steadily rising obesity rates and growing demand for effective weight-loss treatments.
Novo Nordisk confirmed that it has begun adjusting the prices of Wegovy in China, although the company did not disclose a full breakdown of the new pricing structure. According to Chinese business news outlet Yicai, list prices for the two highest dosages of Wegovy have been reduced by as much as 48% in certain provinces. Under the reported changes, the monthly cost for these dosages has fallen to approximately 987 yuan ($141) and 1,284 yuan ($183), marking a substantial decrease compared with previous pricing.
In a statement, Novo Nordisk said the price reduction is aimed at easing the financial burden on patients and improving overall treatment accessibility. The company emphasized that the pricing adjustment aligns with its broader commitment to addressing chronic diseases such as obesity and supporting better long-term health outcomes for patients.
Chinese drug suppliers have also indicated that Eli Lilly’s obesity treatment, Mounjaro, is seeing similar price adjustments, although detailed figures have not been officially confirmed. Both Wegovy and Mounjaro are part of a new generation of GLP-1-based medications that have gained global attention for their effectiveness in weight management and metabolic health.
The price cuts could have a meaningful impact in China, where obesity and related conditions such as type 2 diabetes and cardiovascular disease are becoming more prevalent due to lifestyle changes and urbanization. Lower prices may encourage more patients to seek medical treatment rather than relying solely on diet or unregulated supplements.
For Novo Nordisk and Eli Lilly, reducing prices in China may also help strengthen their competitive positions as domestic pharmaceutical companies accelerate development of similar weight-loss drugs. Overall, the move highlights how global drugmakers are adapting pricing strategies to local markets while responding to rising demand for obesity treatments worldwide.
